# US 2020/0399334 A1 · B*44 restricted peptides for use in immunotherapy against cancers and related methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399334 A1
- Document ID: US20200399334A1
- Status: Published application
- Kind: A1
- Application number: 16/916,447
- Filed: 2020-06-30
- Published: 2020-12-24
- Earliest claimed: 2018-09-17
- Assignees: Immatics Biotechnologies GmbH
- Applicants: Immatics Biotechnologies GmbH
- Inventors: Colette SONG; Heiko SCHUSTER; Daniel Johannes KOWALEWSKI; Oliver SCHOOR; Jens FRITSCHE; Toni WEINSCHENK; Harpreet SINGH
- Web page: https://patentgrep.com/patent/US20200399334A1

## CPC

- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0011: {Cancer antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/18: against material from animals or humans
- C12N 5/0636: {T lymphocytes}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- C07K 7/04: Linear peptides containing only normal peptide links
- C07K 7/06: having 5 to 11 amino acids
- C07K 2319/00: Fusion polypeptide
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

## Claims

### Claim 1

A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 364,
wherein the activated T cells are cytotoxic T cells produced by in vitro contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell,
wherein said cancer is selected from breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gastric cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, urinary bladder carcinoma, and uterine and endometrial cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the T cells are autologous to the patient.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is breast cancer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cancer is cholangiocellular carcinoma.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer is chronic lymphocytic leukemia.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is colorectal cancer.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer is gastric cancer.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer is hepatocellular carcinoma.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cancer is head and neck squamous cell carcinoma.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cancer is non-Hodgkin lymphoma.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cancer is non-small cell lung cancer.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cancer is ovarian cancer.

### Claim 15 (depends on 1)

The method of claim 1, wherein the cancer is esophageal cancer.

### Claim 16 (depends on 1)

The method of claim 1, wherein the cancer is pancreatic cancer.

### Claim 17 (depends on 1)

The method of claim 1, wherein the cancer is prostate cancer.

### Claim 18 (depends on 1)

The method of claim 1, wherein the cancer is renal cell carcinoma.

### Claim 19 (depends on 1)

The method of claim 1, wherein the cancer is urinary bladder carcinoma.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cancer is uterine and endometrial cancer.

### Claim 21 (depends on 4)

The method of claim 4, wherein the adjuvant is IL-7.